Objectives: Information on the long-term effectiveness and tolerability of efavirenz-or nevirapine-based antiretroviral therapy (ART) in Africa is lacking. The primary objective of this retrospective observational study was to compare the long-term clinical and immunological outcomes of efavirenz-versus nevirapine-based first-line ART in a large government clinic in Ghana.
Introduction
Since the availability of combination antiretroviral therapy (ART) has increased in resource-limited countries over the past decade, most programmes have adopted non-nucleoside reverse transcriptase inhibitors (NNRTIs) using either nevirapine or efavirenz within first-line therapy, in line with WHO guidelines. 1 Efavirenz has the advantage of superior clinical, immunological and virological outcome data compared with nevirapine in a number of observational studies, 2 -17 whilst being less likely to cause serious adverse events such as rashes or hepatotoxicity. 7, 8, 12, 14 In both the HIV-CAUSAL and ART-CC studies, the largest comparisons to date, efavirenz was also associated with reduced mortality and AIDS diagnoses compared with nevirapine. 5, 6 Furthermore, efavirenz (unlike nevirapine) can be used with rifampicin in patients with tuberculosis coinfection. 1,7 -11,13 However, in a number of randomized controlled trials there was little evidence favouring either drug in terms of virological outcomes. 18 -20 A meta-analysis has suggested a lower mortality with efavirenz; however, immunological, virological and other clinical outcomes were similar. 21 AWHO-led survey has shown that around two-thirds of developing countries use nevirapine as the main first-line NNRTI in preference to efavirenz, 22 largely due to lower cost and its availability as a generic fixed-dose combination tablet.
Few studies comparing NNRTIs have been conducted in sub-Saharan Africa and these were either small or short-term studies. 2, 7, 23 Moreover, few studies comparing NNRTIs have been conducted in regions where most patients present with advanced HIV infection, as is widely the case in Africa. Given limitations in monitoring the response to ART in many resource-poor countries, particularly the accessibility of HIV viral load assays, and the limited availability of second-line drugs, it is particularly important that first-line drugs are both well tolerated and effective for a long duration. In Ghana, first-line ARTconsists of two nucleoside reverse transcriptase inhibitors (NRTIs) and either efavirenz or nevirapine, if female with reproductive potential. There is also a high rate of tuberculosis and 17% of the HIV-infected population is coinfected with hepatitis B virus (HBV), 24 leading to further challenges with NNRTI-based ART with drug interactions and toxicities. The aim of this study was to determine the long-term effectiveness and tolerability of first-line ART in Ghana, particularly comparing nevirapine and efavirenz.
Patients and methods

Study population and ART
Ethical permission for this study was given by the Committee on Human Research Publications and Ethics of the Kwame Nkrumah University of Science and Technology and the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. Informed consent was not obtained from participants since this was a retrospective, observational study and data were anonymized. Since 2004, patients referred to the HIV clinic in KATH, Kumasi have been treated as part of the National AIDS Control Programme. Patients were referred from a large area of central/northern Ghana. Data on patients were recorded in patients' case notes. Laboratory tests included blood counts, renal/liver function tests and CD4 counts at baseline, with blood counts, liver function and CD4 counts tested every 6 months subsequently. HIV viral load has not been tested routinely and testing for HIV-2 and HBV coinfection has been performed only in limited circumstances. The criteria for starting ART in Ghana followed the WHO guidelines, 1 with a change of the CD4 threshold for initiation from 200 to 350 cells/mm 3 in 2008. First-line ART comprised lamivudine plus either zidovudine or stavudine, plus either nevirapine or efavirenz. The choice between zidovudine or stavudine was determined by availability, but zidovudine was avoided in patients with haemoglobin ,10 g/dL.
Data and study outcomes
Data were extracted from the notes of patients starting ART between January 2004 and December 2010. Information on deaths and other clinical events in patients defaulting clinic appointments were obtained from hospital records in Kumasi and telephone enquiries to relatives or friends of patients. For the present analysis, AIDS-defining events, loss to follow-up, death and adherence to therapy were defined as follows. An AIDS-defining clinical event was defined as the occurrence of any AIDS-defining opportunistic infection or malignancy. Loss to follow-up was defined as missing a clinic appointment by ≥3 months without further attendance at clinic. Death was defined as confirmed death with death certification by a medical practitioner or verbal confirmation of death by a relative or friend. Excellent adherence was defined as taking treatment for .95% of the time by pill counts at clinic visits and poor adherence as failure to achieve this. Treatment-limiting toxicity was defined as drug discontinuation by the treating clinician on account of toxicity. In composite endpoint analysis, treatment failure was defined as a coprimary endpoint of death, occurrence of an AIDS-defining event on therapy or discontinuation of NNRTI for any reason. All-cause NNRTI discontinuations included discontinuations due to toxicity, clinical or immunological failure and patient or physician preference. Immunological responses were analysed using CD4 counts on ART. All analyses were conducted on an intention-to-treat basis and data closed for analysis on 31 December 2011.
Statistical analyses
Parametric and non-parametric methods were used to compare baseline characteristics of continuous data between patients treated with either efavirenz or nevirapine. The Wilcoxon rank sum test was used to compare the two groups, since the baseline continuous data were independent between the patients. Comparisons of dichotomous data were performed using x 2 or Fisher's exact test.
Clinical outcomes
The primary outcome measure of treatment failure was a composite of death, clinical progression or discontinuation of NNRTI for any reason: time to the first occurrence of any of the three coprimary outcome measures was calculated by subtracting the date of the event from the date of initiation of ART. Patients were censored if none of the events in the coprimary endpoint was observed at the time of last visit for patients who were lost to follow-up and at 31 December 2011 for the remainder. Cox proportional hazards regression was used to model the individual and simultaneous effects of the initial NNRTI, baseline variables and adherence on time to the composite endpoint of deaths, clinical progression and NNRTI discontinuation. Potential determinants of therapeutic failure were first tested for possible association with this outcome measure in an unadjusted model for possible inclusion in multivariable models. These variables were recoded into discrete categories: sex (male versus female), age ( . Interactions between covariates were tested by including multiplicative terms in regression models. In the primary outcome analysis, treatment failure was defined as missing equals censored, while in a sensitivity analysis, patients lost to follow-up were considered to have failed therapy (missing equals failure). Similarly, a Cox proportional hazards regression analysis was used to compare the two NNRTIs (efavirenz versus nevirapine) and the two NRTI backbones (stavudine plus lamivudine versus zidovudine plus lamivudine) for their risks of death, loss to follow-up, AIDS-defining events, treatment-limiting discontinuation and all-cause discontinuation of specific antiretroviral medications after adjusting for other potential determinants. Any predictor having significant association with these outcomes at the 10% level in unadjusted analysis was included in adjusted analysis. In multivariable analysis, statistical significance was attained if P,0.05. All P values were two-tailed.
Immunological outcomes
CD4 levels over time after ART initiation were modelled with a generalized linear mixed-effects model by using log link and Poisson distribution. The NNRTI treatment, time since the initiation of therapy, NRTI backbone and their interactions as well as age, gender, baseline CD4 count, WHO clinical stage and calendar year of initiation were specified as fixed effects in the model, whilst a random effect was specified for patients in order to account for the repeated observations over time. The incidence rate ratio (IRR) was reported for the expected number of CD4 cells per mm 3 . All analyses were performed using SAS 9.3.
Results
Study population characteristics
Of 4039 patients identified in this retrospective study, 49 were excluded because they started protease inhibitor-based ART (n¼ 40) or started with NRTI backbones other than zidovudine or stavudine plus lamivudine (n¼ 9). The characteristics of the population studied (n¼ 3990) at the point of ART initiation are shown in Table 1 . Patients starting nevirapine were predominantly women, more likely to use zidovudine (than stavudine) in their NRTI NNRTI-based antiretroviral therapy in Ghana 255 JAC backbone, were younger, had higher median CD4 counts (140 versus 127 cells/mm 3 ) and had lower serum creatinine as well as transaminase concentrations compared with those starting efavirenz.
Composite treatment outcome analysis
As shown in Figure 1 , of the patients who initiated efavirenzcontaining ART (n¼ 2369), 633 (26.7%) experienced at least one event, 1238 (52.3%) did not experience any of the events and 498 (21.0%) were lost to follow-up. Amongst patients initiating nevirapine-containing ART (n¼ 1621), 495 (30.5%) experienced at least one event, 858 (53.0%) did not experience any event and 268 (16.5%) were lost to follow-up without any events. A patient could experience more than one event under follow-up, but the time to the first event was used in multivariable analysis.
The hazard ratio (HR) of treatment failure on nevirapine compared with efavirenz was 1.11 (95% CI: 0.99 -1.27) with a marginal P value of 0.07, as shown in Figure 2 . In primary analysis, the risk of treatment failure among patients on nevirapine compared with efavirenz was 1.07 (95% CI: 0.95-1.21), P ¼ 0.24, in an unadjusted analysis using Cox proportional hazards regression. Given the inequality of loss to follow-up among the two treatment groups, a sensitivity analysis compared the risk of treatment failure to account for confounding due to missing patients where loss to follow-up was treated as failure. Similarly, in this sensitivity analysis, the unadjusted HR of treatment failure among patients on nevirapine compared with efavirenz was 0.94 (95% CI: 0.86 -1.03), P ¼ 0.17 ( Table 2) .
The main determinants of the composite outcome in both primary and sensitivity analyses were initiating therapy at ,40 years old, CD4 cell counts ,200 cells/mm § Forty-nine patients were excluded because they started on a protease inhibitor-based ART (n ¼40) or started with NRTI backbones other than zidovudine +lamivudine or stavudine+lamivudine (n¼9). *A patient could have more than one of the composite events during follow-up. 
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JAC diagnosis at baseline and poor adherence to therapy (all P,0.05), as shown in Table 2 . The combination of stavudine plus lamivudine was also associated with an adverse composite outcome in sensitivity analysis.
Efavirenz versus nevirapine on a backbone of stavudine plus lamivudine (sensitivity analysis)
In an adjusted analysis with the Cox model, the HRs of failure on nevirapine compared with efavirenz were 1.03 (95% CI: 0.87-1.22), P ¼ 0.72, and 0.95 (95% CI: 0.84 -1.08), P¼ 0.45, using either a missing-equals-censored or missing-equals-failure approach, respectively. Thus, on a backbone of stavudine plus lamivudine, there were no significant differences in the risk of failure on either nevirapine or efavirenz.
Efavirenz versus nevirapine on a backbone of zidovudine plus lamivudine (sensitivity analysis)
In a similar adjusted analysis, the HRs of failure on nevirapine compared with efavirenz were 1.20 (95% CI: 1.00 -1.43), P ¼0.05, using a missing-equals-censored assumption, but 1.02 (95% CI: 0.88 -1.19), P ¼ 0.76, using a missing-equals-failure approach.
Clinical outcomes
As shown in Table 3 , the hazards of deaths and loss to follow-up (attrition from the programme) were worse among patients initiated on efavirenz compared with nevirapine on bivariable analysis, but not significantly different on adjusted analysis. Stavudine use was independently associated with an increased risk of death, adjusted HR 1.60 (95% CI: 1.21-2.11). There was no significant difference in the risk of developing new AIDS events on therapy. Patients were significantly less likely to discontinue efavirenz on account of treatment-limiting toxicity (particularly skin rash and hepatotoxicity), adjusted HR 0.53 (95% CI: 0.34-0.82) compared with nevirapine, and stavudine for toxicity, adjusted HR 3.11 (95% CI: 2.72-3.57) compared with zidovudine. Discontinuations of efavirenz for any reason were also lower, adjusted HR 0.74 (95% CI: 0.60 -0.90) compared with nevirapine, whereas discontinuations of stavudine were higher than zidovudine, adjusted HR 2.92 (95% CI: 2.52-3.93).
CD4 count response on ART
The CD4 levels analysed over time using a generalized linear mixed-effects model are shown in Table 4 . The effectiveness of NNRTI therapy with respect to gains in the number of CD4 cells per mm 3 was dependent on the NRTI backbone and the duration on ART. On a zidovudine plus lamivudine backbone, for every Baseline haemoglobin concentration and calendar year of treatment initiation were not significant in unadjusted analysis (not shown in table).
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additional 1 month on ART, the expected gain in CD4 levels was 10.9% less for efavirenz than for nevirapine, adjusted IRR 0.891 (95% CI: 0.875-0.907), whereas for stavudine plus lamivudine there was no significant difference between efavirenz and nevirapine, adjusted IRR 0.997 (95% CI: 0.990-1.004). The plot of predicted CD4 counts for patients on stavudine-containing ART were generally above those on zidovudine-containing ART, as shown in Figure 3 . The effects of other determinants on CD4 counts are shown in Table 4 .
Discussion
The principal aim of this study was to compare the long-term clinical and immunological responses of patients on either efavirenzor nevirapine-based first-line ART in the setting of a busy clinic in a resource-limited country. We found that treatment outcomes were comparable whether efavirenz or nevirapine was chosen to initiate therapy. There were no discernible differences in the risks of death and disease progression between these two NNRTIs on adjusted analyses. There was, however, a 36% lower risk of all-cause discontinuation of efavirenz compared with nevirapine in adjusted analysis, due largely to a 47% lower risk of treatment-limiting toxicity. We also found that an NRTI backbone with stavudine was associated with a 104% increased risk of death, which is moderated by the influence of other covariates in the adjusted model, down to a 60% increased risk compared with a backbone containing zidovudine.
The main findings of this study are in contrast with those in the large HIV-CAUSALand ART-CCobservational studies, where adverse clinical outcomes were significantly less common in patients started on efavirenz. 5, 6 Similarly to the ART-CC study, we found more discontinuations of nevirapine. A recent meta-analysis of a large number of randomized trials and prospective cohort studies identified a .2-fold increased risk of nevirapine discontinuation compared with efavirenz discontinuation, largely due to severe rashes, hepatotoxicity or hypersensitivity reactions, 25 which is not dissimilar to our findings. Two studies have directly compared outcomes of NNRTI-based ART in Africa, 2, 7 whilst one has included comparison of triple combinations containing these NNRTIs. 26 The larger South African study observed significantly more deaths in patients treated with nevirapine as well as more discontinuations, 2 whilst the Senegalese study failed to find significant differences in clinical outcomes, 7 although in both studies virological outcomes were worse in patients taking nevirapine. The largest study in Cote d'Ivoire found no differences in clinical outcomes or CD4 recovery; however, patients were followed for only 18 months after starting ART. 26 In many resource-constrained settings, the CD4 count is used as the main surrogate marker of ART response given that viral load monitoring is not routinely available. Compared with patients on For NNRTI treatment-limiting toxicity and all-cause discontinuation, adjustment for NRTI backbone (zidovudine+lamivudine versus stavudine+lamivudine) was made, whilst for NRTI treatment-limiting toxicity and all-cause discontinuation, adjustment for NNRTI (nevirapine versus efavirenz) was performed. c No adjusted HR calculated because NNRTI was not associated with outcome variable to the specified 10% level in unadjusted analysis.
NNRTI-based antiretroviral therapy in Ghana 259 JAC nevirapine, those on efavirenz gained 1.4% fewer CD4 cells, which though statistically significant, is probably of marginal clinical significance. In conclusion, the long-term clinical and immunological outcomes of ART among Ghanaian HIV-infected patients were more significantly influenced by the NRTI backbone rather than the NNRTI chosen to initiate therapy. Given the excess mortality observed in patients taking stavudine in this and other studies, efforts to phase out its use in sub-Saharan Africa should be prioritized. clinical stages and calendar year of initiation were specified as fixed effects in the model, whilst a random effect was specified for patients in order to account for the repeated observations over time. ZDV, zidovudine; d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine.
